TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2856893

Group type: EXPERIMENTAL
Intervention: 20 mg oral nadolol o.d.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 40 mg oral nadolol o.d.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 80 mg oral nadolol o.d.
Number of subjects: 68

Group type: COMPARATOR
Intervention: 0.25% topical timolol b.d.
Number of subjects: 68

Group type: COMPARATOR
Intervention: 0.5% topical timolol b.d.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Oral nadolol (various doses)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Long-term therapy with oral nadolol
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 68
Study: 31900761

Group type: EXPERIMENTAL
Intervention: Self-regulation group (expressive writing about deepest feelings related to cancer, cognitive reappraisal, and benefit finding over 3 weeks)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Enhanced self-regulation group (expressive writing with reversed topics for weeks 1 and 2)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Cancer-fact group (writing about cancer experiences objectively for 3 weeks)
Number of subjects: 136
Study: 29895289

Group type: EXPERIMENTAL
Intervention: Intermittent IV paracetamol
Number of subjects: 208

Group type: COMPARATOR
Intervention: Continuous IV morphine
Number of subjects: 208
Study: 27619773

Group type: EXPERIMENTAL
Intervention: Corifollitropin alpha (CFA) 150 mg single injection
Number of subjects: 2896

Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH) 200 IU daily injections (ENGAGE) or 300 IU daily injections (PURSUE)
Number of subjects: 2896
Study: 24179986

Group type: EXPERIMENTAL
Intervention: Liner group (firing of 2 layers of paste liner, etched with hydrofluoric acid, treated with silane)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Glaze group (firing of 2 layers of overglaze, etched with hydrofluoric acid, treated with silane)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rocatec group (Rocatec treatment and silane application)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ultrasonic-Rocatec group (Rocatec treatment followed by ultrasonic cleaning and silanization)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Alumina group (sandblasted with alumina)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (as-sintered with no pretreatment)
Number of subjects: 120
Study: 23245940

Group type: EXPERIMENTAL
Intervention: Calendula cream
Number of subjects: 411

Group type: COMPARATOR
Intervention: Essex cream
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 411
Study: 21050564

Group type: EXPERIMENTAL
Intervention: Complete intubation group (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Partial intubation group (n=20)
Number of subjects: 40
Study: 17768173

Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Triple therapy (Ciclosporin + Prednisolone)
Number of subjects: 467

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 467
Study: 17221013

Group type: EXPERIMENTAL
Intervention: Intravenous dipyrone
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intravenous metoclopramide
Number of subjects: 27
Study: 14624420

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 150

Group type: COMPARATOR
Intervention: Elective Wiktor I stent implantation
Number of subjects: 150
Study: 12454761

Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fulvestrant 125 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10379016

Group type: EXPERIMENTAL
Intervention: Soybean oil diet (0.5 g trans fatty acid per 100 g fat)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Semiliquid margarine diet (0.5 g trans fatty acid per 100 g fat)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Soft margarine diet (7.4 g trans fatty acid per 100 g fat)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Shortening diet (9.9 g trans fatty acid per 100 g fat)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Stick margarine diet (20.1 g trans fatty acid per 100 g fat)
Number of subjects: 36
Study: 7735445

Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 57

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 57
Study: 2282972

Group type: EXPERIMENTAL
Intervention: Sultamicillin (50 mg/kg.day or 500 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Amoxycillin (40 mg/kg.day or 250 mg/day)
Number of subjects: 86
Study: 6815695

Group type: EXPERIMENTAL
Intervention: IV L-tryptophan (TRP)
Number of subjects: 10
Study: 31551370

Group type: EXPERIMENTAL
Intervention: BCG and oral polio vaccine (OPV) administered at a single home visit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving information about vaccination opportunities
Number of subjects: 0
Study: 29282085

Group type: EXPERIMENTAL
Intervention: Omega3Q10
Number of subjects: 97

Group type: COMPARATOR
Intervention: Soybean oil
Number of subjects: 97
Study: 25478971

Group type: EXPERIMENTAL
Intervention: New sparse and incomplete factorial matrices for screening membrane protein 2D crystallization
Number of subjects: 16
Study: 24423343

Group type: EXPERIMENTAL
Intervention: 4 month weight loss program
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normal-weight counterparts
Number of subjects: 17
Study: 22154318

Group type: EXPERIMENTAL
Intervention: In-treatment heart rate (HR)
Number of subjects: 9024

Group type: EXPERIMENTAL
Intervention: In-treatment HR of ≥84 beats/min
Number of subjects: 9024

Group type: EXPERIMENTAL
Intervention: Baseline HR as a continuous variable
Number of subjects: 9024

Group type: EXPERIMENTAL
Intervention: Baseline HR of ≥84 beats/min
Number of subjects: 9024
Study: 19670055

Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus risperidone (CogTher + Risp)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus placebo (CogTher + Placebo)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Supportive counselling plus placebo (Supp + Placebo)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Monitoring (no randomization)
Number of subjects: 193
Study: 17138722

Group type: EXPERIMENTAL
Intervention: ID fat infusion with orlistat (120 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ID long-chain fatty acids (LCF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: ID medium-chain fatty acids (MCF)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ID LCF with dexloxiglumide (Dexlox)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ID fat or LCF
Number of subjects: 36

Group type: COMPARATOR
Intervention: ID MCF
Number of subjects: 36
Study: 15200654

Group type: EXPERIMENTAL
Intervention: 0.1 mg x kg(‐1) morphine hydrochloride (M)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.5 mg x kg(‐1) tramadol hydrochloride (T)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 mg.kg(‐1) ketamine hydrochloride (K)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (S)
Number of subjects: 60
Study: 12026029

Group type: EXPERIMENTAL
Intervention: Zinc supplementation or introduction of animal products as complementary foods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional early complementary foods (cereals, fruits, vegetables)
Number of subjects: 0
Study: 10063567

Group type: EXPERIMENTAL
Intervention: 5-year treatment with tamoxifen
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Systemic therapy added to local treatment of isolated locoregional recurrence
Number of subjects: 341
Study: 7970004

Group type: EXPERIMENTAL
Intervention: Lamotrigine (200 to 500 mg daily, with higher dosages up to 700 mg in extension studies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study: 2659718

Group type: EXPERIMENTAL
Intervention: Special premature formula
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 25
Study: 4947832

Group type: EXPERIMENTAL
Intervention: Aluminium-phosphate-adsorbed tetanus toxoid (1-3 injections of 1 ml)
Number of subjects: 1618

Group type: COMPARATOR
Intervention: Placebo (influenza vaccine)
Number of subjects: 1618
Study: 29145711

Group type: EXPERIMENTAL
Intervention: Prehospital antibiotic administration by paramedics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed antibiotic therapy
Number of subjects: 0
Study: 27149935

Group type: EXPERIMENTAL
Intervention: L-DOPA, specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24637869

Group type: EXPERIMENTAL
Intervention: Gene expression profiling score variability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ordinal gene expression profiling scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Threshold gene expression profiling scores
Number of subjects: 0
Study: 22185955

Group type: EXPERIMENTAL
Intervention: Chiropractic treatment (spinal manipulation) for 4 weeks
Number of subjects: 115

Group type: COMPARATOR
Intervention: Self-management (minimal intervention) for 4 weeks
Number of subjects: 115
Study: 20610576

Group type: EXPERIMENTAL
Intervention: Evaluation to Sign Consent form
Number of subjects: 100
Study: 19100116

Group type: EXPERIMENTAL
Intervention: Pacing at right ventricular outflow tract (uncommon pacing group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pacing at ventricular cardiac apex (common pacing group)
Number of subjects: 40
Study: 16896737

Group type: EXPERIMENTAL
Intervention: Fan airflow (FAN) during exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: No cooling (NC) during exercise
Number of subjects: 10
Study: 12787156

Group type: EXPERIMENTAL
Intervention: Signposts intervention system (group support, telephone support, self‐directed modes)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Self‐directed mode of Signposts intervention
Number of subjects: 115
Study: 10827386

Group type: EXPERIMENTAL
Intervention: Rescue percutaneous transluminal coronary angioplasty (PTCA) after failed fibrinolysis (TIMI 0 to 1 flow)
Number of subjects: 2433

Group type: COMPARATOR
Intervention: Conservative therapy after fibrinolytic therapy
Number of subjects: 2433
Study: 9395034

Group type: EXPERIMENTAL
Intervention: Study S7823
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Study S8124
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Study S8600
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Study S7823 (age < 50 years)
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Study S8124 (age < 50 years)
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Study S8600 (age < 50 years)
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Study S7823 (age < 50 years, complete remission)
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Study S8124 (age < 50 years, complete remission)
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Study S8600 (age < 50 years, standard dose cytarabine)
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Study S8600 (age < 50 years, high dose cytarabine)
Number of subjects: 2083
Study: 8383390

Group type: COMPARATOR
Intervention: Immune serum globulin (Ig) 0.06 ml/kg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A virus vaccine (iHAV) single dose 25 ng
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A virus vaccine (iHAV) booster dose
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 3769702

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg after each meal and at bedtime (200 mg qid)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg after breakfast and at bedtime (400 mg bid)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo tablets (control)
Number of subjects: 5
Study: 3052675

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 80

Group type: COMPARATOR
Intervention: Infiltration of lignocaine solution
Number of subjects: 80
Study: 31441233

Group type: EXPERIMENTAL
Intervention: Sitting with 3-minute bouts of simple resistance activities (SRAs) every 30 minutes
Number of subjects: 19

Group type: COMPARATOR
Intervention: Uninterrupted sitting
Number of subjects: 19
Study: 28342647

Group type: EXPERIMENTAL
Intervention: 40 Gy (EQD2Gy) to the elective lymph node regions
Number of subjects: 233
Study: 24725373

Group type: EXPERIMENTAL
Intervention: Histamine provocation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bronchodilator use (salbutamol)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Capnovolumetry
Number of subjects: 40
Study: 23565002

Group type: EXPERIMENTAL
Intervention: Earplugs
Number of subjects: 400

Group type: COMPARATOR
Intervention: No earplugs (Control)
Number of subjects: 400
Study: 21798535

Group type: EXPERIMENTAL
Intervention: Breathable panty liners (BPLs) worn for 10‐12 hours each day for 75 consecutive days
Number of subjects: 107
Study: 19553300

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 4 months followed by rapid weaning to replacement foods
Number of subjects: 593

Group type: COMPARATOR
Intervention: Exclusive breastfeeding for 6 months followed by introduction of complementary foods and continued breastfeeding
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Not breastfeeding
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Breastfeeding practice
Number of subjects: 593
Study: 16428253

Group type: EXPERIMENTAL
Intervention: 12 month collaborative care intervention (IMPACT)
Number of subjects: 1801

Group type: COMPARATOR
Intervention: usual care for depression
Number of subjects: 1801
Study: 12440551

Group type: EXPERIMENTAL
Intervention: Ionized bracelet
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo bracelet
Number of subjects: 610
Study: 10523367

Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure measurement
Number of subjects: 2650

Group type: EXPERIMENTAL
Intervention: Daytime ambulatory blood pressure measurement
Number of subjects: 2650

Group type: COMPARATOR
Intervention: Clinic blood pressure measurement by physician
Number of subjects: 2650

Group type: COMPARATOR
Intervention: Clinic blood pressure measurement by nurse
Number of subjects: 2650

Group type: COMPARATOR
Intervention: Home blood pressure measurement by nurse
Number of subjects: 2650

Group type: COMPARATOR
Intervention: Self-measured blood pressure
Number of subjects: 2650

Group type: COMPARATOR
Intervention: Clinic blood pressure measurement by physician (subgroup with self-measurement)
Number of subjects: 2650

Group type: COMPARATOR
Intervention: Clinic blood pressure measurement by nurse (subgroup with self-measurement)
Number of subjects: 2650

Group type: COMPARATOR
Intervention: Home blood pressure measurement by nurse (subgroup with self-measurement)
Number of subjects: 2650

Group type: COMPARATOR
Intervention: Daytime ambulatory blood pressure measurement (subgroup with self-measurement)
Number of subjects: 2650

Group type: COMPARATOR
Intervention: 24-hour ambulatory blood pressure measurement (subgroup with self-measurement)
Number of subjects: 2650
Study: 7722855

Group type: EXPERIMENTAL
Intervention: Simulating borderline personality disorder on the MMPI-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulating major depression on the MMPI-2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical comparison group diagnosed with borderline personality disorder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Honest responses to the MMPI-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: F scale analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Borderline Personality Disorder Scale (BPDsc) analysis
Number of subjects: 0
Study: 1817055

Group type: EXPERIMENTAL
Intervention: Initial periodontal therapy consisting of a single subgingival root debridement procedure followed by repeated monthly subgingival irrigations over a period of 6 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Single root debridement procedure
Number of subjects: 23
Study: 7018187

Group type: EXPERIMENTAL
Intervention: Non-selective beta-blockade
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cardioselective beta-blockade
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cold pressor test
Number of subjects: 13

Group type: COMPARATOR
Intervention: Mental arithmetics
Number of subjects: 13
Study: 31658113

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine lozenge
Number of subjects: 723

Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine lozenge
Number of subjects: 723
Study: 30442692

Group type: EXPERIMENTAL
Intervention: 2-layered susceptibility vessel sign and high overestimation ratio on pretreatment brain T2* sequences
Number of subjects: 260
Study: 26198808

Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 4 weeks (2q4)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 8 weeks after 5 monthly doses (2q8)
Number of subjects: 872

Group type: COMPARATOR
Intervention: Laser control
Number of subjects: 872
Study: 23750019

Group type: EXPERIMENTAL
Intervention: Group Lifestyle Modification Program (Group LMP)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Self-Guided Lifestyle Modification Program (Self-Guided LMP)
Number of subjects: 169
Study: 22315807

Group type: EXPERIMENTAL
Intervention: Electro acupuncture therapy (10 sittings on alternate days at GB and UB points)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional drug therapy (oral Valdecoxib) with supervised physiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 60
Study: 18445172

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of insulin aspart
Number of subjects: 21

Group type: COMPARATOR
Intervention: Insulin injection of insulin glargine
Number of subjects: 21
Study: 16941338

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART) for 24 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated subjects
Number of subjects: 20
Study: 14622632

Group type: EXPERIMENTAL
Intervention: Individualised fluid prescription (30 ml/kg body weight/24 h, max 35 ml/kg body weight/24 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard fluid intake (maximum 1.5 l)
Number of subjects: 0
Study: 11198484

Group type: EXPERIMENTAL
Intervention: Noninvasive measurement of beat-to-beat blood pressure during the Valsalva maneuver
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Invasive measurement of beat-to-beat blood pressure
Number of subjects: 70
Study: 8625244

Group type: EXPERIMENTAL
Intervention: M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin)
Number of subjects: 57

Group type: COMPARATOR
Intervention: M-VECa (methotrexate, vinblastine, epirubicin, and carboplatin)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: M-VEC
Number of subjects: 57

Group type: COMPARATOR
Intervention: M-VECa
Number of subjects: 57
Study: 10122538

Group type: EXPERIMENTAL
Intervention: Medicaid HMO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fee-for-Service (FFS)
Number of subjects: 0
Study: 6141182

Group type: EXPERIMENTAL
Intervention: Negative practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desensitization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 0
Study: 31023762

Group type: EXPERIMENTAL
Intervention: Plasma Lp(a) levels measured at baseline
Number of subjects: 9698
Study: 29602346

Group type: EXPERIMENTAL
Intervention: Grafted facemask therapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ungrafted facemask therapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Facemask therapy (grafted and ungrafted)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Grafted group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ungrafted group
Number of subjects: 61
Study: 27195774

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) with erythropoietin (EPO) - 1 g IV FCM plus 40,000 IU subcutaneous EPO
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) without erythropoietin (EPO) - 1 g IV FCM plus subcutaneous placebo
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo - IV and subcutaneous placebo
Number of subjects: 306
Study: 25493656

Group type: EXPERIMENTAL
Intervention: Non-ICU hospitalized patients
Number of subjects: 11243

Group type: EXPERIMENTAL
Intervention: ICU patients
Number of subjects: 11243

Group type: COMPARATOR
Intervention: Not hospitalized (control group)
Number of subjects: 11243
Study: 23077155

Group type: EXPERIMENTAL
Intervention: Oral steroid for 10 days (group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection (ITDI) 4 times (group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of oral steroid and ITDI (group III)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Overall recovery rate across all groups
Number of subjects: 60
Study: 19912211

Group type: EXPERIMENTAL
Intervention: Bipolar TURP (Surgmaster TURis, Olympus, Tokyo, Japan)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Monopolar TURP (24 F, Storz, Tübingen, Germany)
Number of subjects: 202
Study: 17994222

Group type: EXPERIMENTAL
Intervention: Routine prescription of daily CXRs
Number of subjects: 165

Group type: COMPARATOR
Intervention: Restrictive prescription of clinically indicated CXRs
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 165
Study: 16906020

Group type: EXPERIMENTAL
Intervention: Cyp3A5*3 homozygotes
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Less than three copies of MDR-1 polymorphisms (T-129C, C3435T, G2677T)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (Cyp3A5*3 homozygotes)
Number of subjects: 44
Study: 12802024

Group type: COMPARATOR
Intervention: COPP-ABVD
Number of subjects: 1195

Group type: COMPARATOR
Intervention: BEACOPP
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: Increased-dose BEACOPP
Number of subjects: 1195
Study: 10814923

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-coated circuits
Number of subjects: 39